Suchen
Transcode Therapeutics Inc
RNAZZur Watchlist hinzufügen
6.210USD
+0.970+18.51%
Handelsschluss 06/30, 16:00（ET）Kurse um 15 Minuten verzögert
5.90MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Transcode Therapeutics Inc Unternehmen
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc Informationen
BörsenkürzelRNAZ
Name des UnternehmensTranscode Therapeutics Inc
IPO-datumApr 28, 2021
CEOCalais (Philippe P)
Anzahl der mitarbeiter7
WertpapierartOrdinary Share
GeschäftsjahresendeApr 28
Addresse6 Liberty Square
StadtBOSTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02109
Telefon18573016857
Websitehttps://www.transcodetherapeutics.com/
BörsenkürzelRNAZ
IPO-datumApr 28, 2021
CEOCalais (Philippe P)
Führungskräfte von Transcode Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Transcode Therapeutics Inc?
Die fünf größten Anteilseigner von Transcode Therapeutics Inc sind: Mr. Thomas A. (Tom) Fitzgerald
Wie viele Institutionen halten Anteile an Transcode Therapeutics Inc (RNAZ)?
Mit Stand vom 2026Q1 halten 37 Institutionen Anteile an Transcode Therapeutics Inc, mit einem Gesamtmarktwert von etwa 77.85K, was 8.49% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -42306.00 gestiegen.